- Home
- ESTA vs KNSA Comparison
ESTA vs KNSA Comparison
Compare ESTA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTA
- KNSA
- Stock Information
- Founded
- ESTA 2004
- KNSA 2015
- Country
- ESTA Costa Rica
- KNSA United Kingdom
- Employees
- ESTA N/A
- KNSA N/A
- Industry
- ESTA Industrial Specialties
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- ESTA Health Care
- KNSA Health Care
- Exchange
- ESTA Nasdaq
- KNSA Nasdaq
- Market Cap
- ESTA 1.3B
- KNSA 1.4B
- IPO Year
- ESTA 2018
- KNSA 2018
- Fundamental
- Price
- ESTA $34.56
- KNSA $18.54
- Analyst Decision
- ESTA Buy
- KNSA Strong Buy
- Analyst Count
- ESTA 6
- KNSA 5
- Target Price
- ESTA $60.50
- KNSA $36.60
- AVG Volume (30 Days)
- ESTA 736.4K
- KNSA 485.3K
- Earning Date
- ESTA 02-26-2025
- KNSA 02-26-2025
- Dividend Yield
- ESTA N/A
- KNSA N/A
- EPS Growth
- ESTA N/A
- KNSA N/A
- EPS
- ESTA N/A
- KNSA N/A
- Revenue
- ESTA $153,071,000.00
- KNSA $384,098,000.00
- Revenue This Year
- ESTA $2.81
- KNSA $60.05
- Revenue Next Year
- ESTA $23.95
- KNSA $36.74
- P/E Ratio
- ESTA N/A
- KNSA N/A
- Revenue Growth
- ESTA N/A
- KNSA 54.41
- 52 Week Low
- ESTA $30.20
- KNSA $16.56
- 52 Week High
- ESTA $60.12
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- ESTA 32.26
- KNSA 35.62
- Support Level
- ESTA $30.20
- KNSA $17.82
- Resistance Level
- ESTA $47.71
- KNSA $19.05
- Average True Range (ATR)
- ESTA 2.63
- KNSA 0.63
- MACD
- ESTA -1.35
- KNSA -0.08
- Stochastic Oscillator
- ESTA 24.90
- KNSA 26.09
About ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.